No­var­tis qui­et­ly used a PRV to speed the ap­proval of its new rare blood dis­or­der drug

The FDA dis­closed on Fri­day that No­var­tis’ ap­proval for its new $550,000 per year treat­ment for adults with parox­ys­mal noc­tur­nal he­mo­glo­bin­uria, or PNH, a rare …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER